Back to Press Releases

Revance Celebrates Distribution of One Million Vials of DAXXIFY® in the U.S.

The milestone comes just three years after DAXXIFY® received FDA approval.

1M Daxxify Screenshot 2025-09-15 at 3.45.27 PM.png

Nashville, TN – September 17, 2025 – Revance, a fast-growing global aesthetics and skincare company, announces today that it has achieved the key milestone of having distributed one million vials of DAXXIFY® (daxibotulinumtoxinA-lanm) for aesthetics in the U.S. This achievement comes only three years after the product’s FDA approval and highlights the position DAXXIFY® plays as the fastest-growing neurotoxin in the country.1

DAXXIFY® is the only neurotoxin with a proprietary peptide formulation. This frown line treatment, made without human or animal-based components, represents the first major advancement in neurotoxin technology in more than 20 years. It has a unique clinical profile that combines a fast onset with the ability to smooth even the deepest lines and deliver long-lasting results.2-9*

“Reaching the one million vial mark represents an important milestone in the advancement of aesthetic medicine and of DAXXIFY®,” says Conor Gallagher PhD, Chief Scientific Officer of Revance. “This achievement highlights the trust our provider partners place in our peptide formulated neurotoxin and reflects the value they place in innovation that translates into true clinical outcomes. We are encouraged by the growing body of real-world experience, and we are actively continuing to expand the science and data supporting DAXXIFY®.”

This milestone comes at a time when patients are more discerning than ever about ingredients in both the products and treatments they select. DAXXIFY® continues to position itself as a trusted choice for frown line treatments among patients and providers alike, resulting in this major accomplishment.

Learn more at Revance.com and DAXXIFY.com.

About Revance:
Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.

Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the Teoxane RHA® Collection, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the Teoxane RHA® Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

RHA® is a trademark of TEOXANE SA.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

Media Contact:
EvolveMKD
Revance@EvolveMKD.com

References:

  1. DOF US Facial Injectables Market Tracker 2025, p10A.
  2. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2022.
  3. Botox® Cosmetic. Prescribing Information. Allergan Inc; 2020.
  4. Xeomin®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.
  5. Dysport®. Prescribing Information. Ipsen Biopharm Ltd; 2023.
  6. Jeuveau®. Prescribing Information. Evolus, Inc; 2020.
  7. Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2021.
  8. Bertucci et al. J Am Acad Dermatol. 2020;82(4):838-845.
  9. Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023.

*Results as early as the next day and typically within 2 days. Based on pooled patient diary data from SAKURA 1 and SAKURA 2. 74% had an improvement at week 4 per both physician’s and patient’s assessments.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.